ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress
Portfolio Pulse from Benzinga Newsdesk
ImmunoGen Inc. announced updated data from an interim analysis of the Phase 2 CADENZA trial of pivekimab sunirine in patients with BPDCN. The data will be presented at the EHA 2023 Congress in Frankfurt, Germany.
June 09, 2023 | 7:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ImmunoGen's updated data from the Phase 2 CADENZA trial of pivekimab sunirine in BPDCN patients may impact the company's stock price.
The updated data from the Phase 2 CADENZA trial of pivekimab sunirine in BPDCN patients is a significant milestone for ImmunoGen. Positive results may lead to increased investor confidence and potential stock price appreciation. However, the final impact will depend on the actual data presented at the EHA 2023 Congress.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100